ISTA Pharmaceuticals is initiating Phase III clinical trials of once-daily formulation of Xibrom for the treatment of ocular pain and inflammation following cataract surgery.

The FDA has already approved the twice-daily Xibrom for the treatment of ocular inflammation and reduction of ocular pain following cataract surgery.